MedPath

Study of Circulating Microparticles in Giant Cell Arteritis

Conditions
Giant Cell Arteritis
Acute Phase
Registration Number
NCT02333708
Lead Sponsor
University Hospital, Caen
Brief Summary

To demonstrate that microparticles (MPs), having a powerful procoagulant potential, are in larger amounts in the blood of patients with histologically proven giant cell arteritis (GCA), compared with patients matched for age, sex and with or without inflammatory syndrome.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
75
Inclusion Criteria
  • Men and women ≥ 18 years of age Patient affiliated to social security regimen

  • Informed and having signed the consent form to take part in the study.

  • Diagnosis of GCA, meeting at least 3 of the following 5 American College of Rheumatology (ACR) criteria for the diagnosis of GCA, including inflammatory syndrome and having

    • Either temporal artery biopsy showing characteristic GCA abnormality
    • Or inflammatory arteritis on imaging examination
Exclusion Criteria
  • Persons under protection of the court or guardianship
  • Inability to understand or to follow study procedures
  • Dementia
  • cancer diagnosed within the previous 5 years (except for non-melanoma skin cancer or in situ carcinoma of the cervix)non-contributory or inconclusive temporal artery biopsy
  • Any conditions that might interfere with MPs level: diabetes, recent endo-arterial gesture, current treatment with corticosteroids.
  • Participation in another ongoing clinical trial Current anticoagulant therapy
  • Active infectious disease

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Level of microparticles in the blood of patients with histologically proven giant cell arteritis.Baseline

Level of microparticles (MPs) in the blood of patients with histologically proven giant cell arteritis (GCA), compared with patients matched for age, sex and with or without inflammatory syndrome.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Centre Hospitalier Universitaire Côte de Nacre

🇫🇷

Caen, France

Centre Hospitalier Universitaire Côte de Nacre
🇫🇷Caen, France
Boris BIENVENU
Contact
+33231064579

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.